Conduit Pharmaceuticals (CDT) announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company’s first patent filings for AZD5658. These filings represent a significant expansion of Conduit’s intellectual property portfolio, further supporting its strategy to advance and license differentiated, IP-rich pharmaceutical assets. The new patents reflect combinations of Conduit’s lead assets with existing therapies, identified through extensive AI-led analysis conducted in collaboration with Sarborg. This partnership continues to yield valuable insights, enabling the Company to generate novel, data-driven IP with strong strategic and commercial relevance.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDT:
- Conduit Pharmaceuticals Enters Joint Development Agreement
- Conduit Pharmaceuticals enters joint development agreement with Manoira
- Conduit Pharmaceuticals Sets 2025 Annual Meeting Date
- Conduit Pharmaceuticals approved to transfer listing to Nasdaq Capital Market
- Conduit Pharmaceuticals regains Nasdaq compliance